drugset / Trial / NCT06315257
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Phase 1
Recruiting
32 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
Timeline
- Start
- 2025-07-23
- Primary completion
- 2029-06
- Completion
- 2030-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TA-HPV | Vaccine | 250000 unknown | Other |
| Subject | TA-HPV | Vaccine | 1e+07 unknown | Other |
| Subject | pBI-11 DNA | Unknown | 3 mg | Intramuscular |